Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates

Muming Yu1, Bin Lu1, Yancun Liu1

  • 1Emergency Department, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China.

Insights

Tumor cells resistant to anoikis can metastasize. This study shows that inhibiting Tim-3 in clear cell renal cell carcinoma (ccRCC) enhances anoikis, reducing tumor cell invasion and suggesting Tim-3 as a therapeutic target.

Area of Science:

  • Oncology
  • Cell Biology
  • Cancer Metastasis

Background:

  • Anoikis resistance is a hallmark of metastatic cancer.
  • Clear cell renal cell carcinoma (ccRCC) poses a significant health challenge.
  • The role of T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) in ccRCC metastasis requires further elucidation.

Purpose of the Study:

  • To investigate the role of Tim-3 in anoikis.
  • To determine the influence of Tim-3 on clear cell renal cell carcinoma (ccRCC) cell invasion.
  • To explore Tim-3 as a potential therapeutic target for ccRCC.

Main Methods:

  • Utilized polyhydroxylethylmethacrylate (poly-HEMA) to induce anoikis in ccRCC cell lines (786-O and Caki-2).
  • Assessed Tim-3 expression via RT-qPCR and Western blot.
  • Quantified anoikis, apoptosis, E-cadherin, N-cadherin, and cell invasion using various assays, including flow cytometry and cell invasion kits.

Main Results:

  • Extracellular matrix (ECM) detachment reduced Tim-3 expression in ccRCC cells.
  • Small interfering RNA (siRNA) mediated Tim-3 knockdown exacerbated anoikis and reduced invasion.
  • Tim-3 interference led to E-cadherin upregulation and N-cadherin downregulation.

Conclusions:

  • Tim-3 expression is linked to anoikis resistance and invasion in ccRCC.
  • Interfering with Tim-3 can enhance anoikis and attenuate ccRCC cell invasion.
  • Tim-3 represents a promising therapeutic target for ccRCC treatment.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K